Integrating Therapies for Alcohol Use Disorder in Alcohol-Associated Hepatitis Clinical Trials: Advancing Composite Endpoints for Improved Outcomes

Integrating Therapies for Alcohol Use Disorder in Alcohol-Associated Hepatitis Clinical Trials: Advancing Composite Endpoints for Improved Outcomes

Alcohol-associated hepatitis (AH) carries high morbidity and mortality, with no approved therapies addressing both liver injury and alcohol misuse. This article explores integrated trial designs using composite endpoints combining liver and alcohol-related outcomes, exemplified by the ITAALD trial.
GLP-1 Receptor Agonists May Reduce Hospital Admissions for Alcohol and Substance Use Disorders: Insights from a Swedish Nationwide Study

GLP-1 Receptor Agonists May Reduce Hospital Admissions for Alcohol and Substance Use Disorders: Insights from a Swedish Nationwide Study

This Swedish register-based study reveals that GLP-1 receptor agonists are associated with significantly reduced hospitalisations for alcohol and substance use disorders during treatment, with some lasting benefits after discontinuation of therapy for alcohol use disorder.
Elevated Risk of Alcohol-Related Liver Disease and Mortality in Patients Undergoing Treatment for Alcohol Use Disorder: Insights from a Nationwide Danish Cohort

Elevated Risk of Alcohol-Related Liver Disease and Mortality in Patients Undergoing Treatment for Alcohol Use Disorder: Insights from a Nationwide Danish Cohort

This study quantifies the heightened risk of alcohol-related liver disease, cancer, cardiovascular mortality, and all-cause death among individuals receiving treatment for alcohol use disorder compared to the general population, emphasizing the need for targeted screening and integrated care.